Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 2
2013 1
2014 4
2015 3
2016 3
2017 5
2018 5
2019 8
2020 9
2021 18
2022 6
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Oligoprogression in Non-Small Cell Lung Cancer.
Harada D, Takigawa N. Harada D, et al. Cancers (Basel). 2021 Nov 20;13(22):5823. doi: 10.3390/cancers13225823. Cancers (Basel). 2021. PMID: 34830977 Free PMC article. Review.
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
Morita A, Ichihara E, Inoue K, Fujiwara K, Yokoyama T, Harada D, Ando C, Kano H, Oda N, Tamura T, Ochi N, Kawai H, Inoue M, Hara N, Fujimoto N, Ichikawa H, Oze I, Hotta K, Maeda Y, Kiura K. Morita A, et al. Among authors: harada d. Int J Cancer. 2024 May 1;154(9):1607-1615. doi: 10.1002/ijc.34842. Epub 2024 Jan 9. Int J Cancer. 2024. PMID: 38196128
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).
Nakamichi S, Kubota K, Misumi T, Kondo T, Murakami S, Shiraishi Y, Imai H, Harada D, Isobe K, Itani H, Takata S, Wakui H, Misumi Y, Ikeda S, Asao T, Furuya N, Hosokawa S, Kobayashi Y, Takiguchi Y, Okamoto H. Nakamichi S, et al. Among authors: harada d. Clin Cancer Res. 2024 Mar 15;30(6):1104-1110. doi: 10.1158/1078-0432.CCR-23-2568. Clin Cancer Res. 2024. PMID: 38165684 Free PMC article. Clinical Trial.
Cryopreservation of Marchantia polymorpha spermatozoa.
Togawa T, Adachi T, Harada D, Mitani T, Tanaka D, Ishizaki K, Kohchi T, Yamato KT. Togawa T, et al. Among authors: harada d. J Plant Res. 2018 Nov;131(6):1047-1054. doi: 10.1007/s10265-018-1059-0. Epub 2018 Jul 31. J Plant Res. 2018. PMID: 30066035
Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells.
Nakagawa N, Miyake N, Ochi N, Yamane H, Takeyama M, Nagasaki Y, Ikeda T, Yokota E, Fukazawa T, Nakanishi H, Harada D, Kiura K, Takigawa N. Nakagawa N, et al. Among authors: harada d. Exp Cell Res. 2021 Dec 15;409(2):112940. doi: 10.1016/j.yexcr.2021.112940. Epub 2021 Nov 19. Exp Cell Res. 2021. PMID: 34808132
Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801.
Hosokawa S, Ichihara E, Harada D, Kuyama S, Inoue K, Gemba K, Ichikawa H, Kato Y, Oda N, Oze I, Tamura T, Kozuki T, Umeno T, Kubo T, Hotta K, Bessho A, Maeda Y, Kiura K. Hosokawa S, et al. Among authors: harada d. Int J Clin Oncol. 2022 Jul;27(7):1139-1144. doi: 10.1007/s10147-022-02164-2. Epub 2022 May 10. Int J Clin Oncol. 2022. PMID: 35534642 Clinical Trial.
61 results